Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

GALECTIN THERAPEUTICS INC.

(GALT)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Galectin Therapeutics : HC Wainwright Adjusts Price Target on Galectin Therapeutics to $14 From $12, Maintains Buy Rating

04/16/2021 | 11:19am EST


ę MT Newswires 2021
All news about GALECTIN THERAPEUTICS INC.
11/15GALECTIN THERAPEUTICS : Reports Financial Results for the Quarter Ended September 30, 2021..
PU
11/15Galectin Therapeutics Reports Financial Results for the Quarter Ended September 30, 202..
GL
11/15GALECTIN THERAPEUTICS INC Management's Discussion and Analysis of Financial Condition ..
AQ
11/15Galectin Therapeutics Inc. Reports Earnings Results for the Third Quarter and Nine Mont..
CI
11/15NORTH AMERICAN MORNING BRIEFING : Stock Futures -2-
DJ
11/08Galectin Therapeutics to Present Six Scientific Abstracts at The Liver Meeting 2021, Ho..
AQ
11/05UPDATE – Galectin Therapeutics to Present Six Scientific Abstracts at The Liver M..
GL
11/05UPDATE – Galectin Therapeutics to Present Six Scientific Abstracts at The Liver M..
GL
10/28Galectin Pharmaceuticals to Present Six Scientific Abstracts at The Liver Meeting 2021,..
AQ
10/27Galectin Pharmaceuticals to Present Six Scientific Abstracts at The Liver Meeting&trade..
AQ
More news
Analyst Recommendations on GALECTIN THERAPEUTICS INC.
More recommendations
Financials (USD)
Sales 2021 - - -
Net income 2021 -34,9 M - -
Net Debt 2021 - - -
P/E ratio 2021 -4,36x
Yield 2021 -
Capitalization 153 M 153 M -
Capi. / Sales 2021 -
Capi. / Sales 2022 -
Nbr of Employees 6
Free-Float 70,5%
Chart GALECTIN THERAPEUTICS INC.
Duration : Period :
Galectin Therapeutics Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends GALECTIN THERAPEUTICS INC.
Short TermMid-TermLong Term
TrendsBearishBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 1
Last Close Price 2,57 $
Average target price 14,00 $
Spread / Average Target 445%
EPS Revisions
Managers and Directors
Joel Lewis President, Chief Executive Officer & Director
Jack W. Callicutt Chief Financial Officer & Secretary
Richard E. Uihlein Chairman
Pol F. Boudes Chief Medical Officer
Ezra R. lowe Executive Director-Clinical
Sector and Competitors
1st jan.Capi. (M$)
GALECTIN THERAPEUTICS INC.14.73%153
MODERNA, INC.215.53%133 648
LONZA GROUP AG29.85%59 443
IQVIA HOLDINGS INC.46.26%50 064
SEAGEN INC.-3.22%30 994
CELLTRION, INC.-40.39%24 431